Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC. | 2025-10-16 18:21:41 | 534 | -2.78 | -0.52 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TMO | 0000097745 | THERMO FISHER SCIENTIFIC INC. | US8835561023 | HCHV7422L5HDJZCRFL38 | 042209186 | NYSE | 3829 | Measuring & Controlling Devices, NEC | 1231 | DE | 168 THIRD AVENUE | WALTHAM | MA | 02451 | UNITED STATES | US | 7816221000 | 168 THIRD AVENUE, WALTHAM, MA, 02451 | 168 THIRD AVENUE, WALTHAM, MA, 02451 | THERMO ELECTRON CORP | Laboratory equipment | 1956 | Marc N. Casper | 125,000 | https://www.thermofisher.com/ | 211,032,682,000 | 444,366,652 | 377,612,121 | Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021). | 2025-10-10 19:03:06 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 211,032,682,000 | 9,856,066,000 | 4.8992 | 377,261,182 | -4,051,086 | -1.0624 |
| 2023 | 201,176,616,000 | -13,405,749,000 | -6.2474 | 381,312,268 | -4,117,809 | -1.0684 |
| 2022 | 214,582,365,000 | 12,910,313,000 | 6.4016 | 385,430,077 | -5,761,693 | -1.4729 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Michel Lagarde | Chief Operating Officer, Executive Vice President | 2024 | 1,132,299 | — | 3,818,809 | 2,047,650 | 136,963 | 12,778,317 |
| Gianluca Pettiti | Executive Vice President | 2024 | 956,558 | — | 3,512,787 | 1,585,686 | 127,683 | 11,340,424 |
| Marc N. Casper | Chief Executive Officer, Chairman, President | 2024 | 1,740,000 | — | 8,194,766 | 5,506,578 | 537,486 | 30,449,599 |
| Stephen Williamson | Chief Financial Officer, Senior Vice President | 2024 | 1,047,575 | — | 3,299,636 | 1,815,500 | 145,073 | 11,087,581 |
| Frederick Lowery | Executive Vice President | 2024 | 881,558 | — | 2,596,408 | 1,328,508 | 115,181 | 8,529,377 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 75,000 |
| 2018 | 70,000 |
| 2017 | 70,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 42,879,000,000 | 42,857,000,000 | 44,915,000,000 |
| Cost Of Revenue | 3,559,000,000 | 13,168,000,000 | 14,247,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 1,390,000,000 | 1,337,000,000 | 1,471,000,000 |
| General And Administrative Expenses | 8,595,000,000 | 8,445,000,000 | 8,993,000,000 |
| Operating Expenses | 35,542,000,000 | 35,998,000,000 | 36,522,000,000 |
| Operating Income | 7,337,000,000 | 6,859,000,000 | 8,393,000,000 |
| Net Income | 6,338,000,000 | 5,955,000,000 | 6,960,000,000 |
| Earnings Per Share Basic | 16.58 | 15.52 | 17.75 |
| Earnings Per Share Diluted | 16.53 | 15.45 | 17.63 |
| Weighted Average Shares Outstanding Basic | 382,000,000 | 386,000,000 | 392,000,000 |
| Weighted Average Shares Outstanding Diluted | 383,000,000 | 388,000,000 | 394,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 4,009,000,000 | 8,077,000,000 | 8,524,000,000 |
| Marketable Securities Current | 1,561,000,000 | — | — |
| Accounts Receivable | 8,191,000,000 | 8,221,000,000 | 8,115,000,000 |
| Inventories | 4,978,000,000 | 5,088,000,000 | 5,634,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,964,000,000 | 1,760,000,000 | 1,644,000,000 |
| Total Assets Current | 22,137,000,000 | 24,589,000,000 | 25,229,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 9,306,000,000 | 9,448,000,000 | 9,280,000,000 |
| Other Assets Non Current | 4,492,000,000 | 3,999,000,000 | 4,007,000,000 |
| Total Assets Non Current | 10,795,000,000 | 11,004,000,000 | 10,873,000,000 |
| Total Assets | 97,321,000,000 | 98,726,000,000 | 97,154,000,000 |
| Accounts Payable | 3,079,000,000 | 2,872,000,000 | 3,381,000,000 |
| Deferred Revenue | 2,852,000,000 | 2,689,000,000 | 2,601,000,000 |
| Short Term Debt | 2,214,000,000 | 3,609,000,000 | 5,579,000,000 |
| Other Liabilities Current | 3,199,000,000 | 3,246,000,000 | 3,354,000,000 |
| Total Liabilities Current | 13,332,000,000 | 14,012,000,000 | 17,010,000,000 |
| Long Term Debt | 31,072,000,000 | 34,727,000,000 | 34,278,000,000 |
| Other Liabilities Non Current | 3,989,000,000 | 4,642,000,000 | 4,238,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 444,000,000 | 442,000,000 | 441,000,000 |
| Retained Earnings | 53,102,000,000 | 47,364,000,000 | 41,910,000,000 |
| Accumulated Other Comprehensive Income | -2,697,000,000 | -3,224,000,000 | -3,099,000,000 |
| Total Shareholders Equity | 49,584,000,000 | 46,735,000,000 | 43,978,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,156,000,000 | 1,068,000,000 | 986,000,000 |
| Share Based Compensation Expense | 301,000,000 | 278,000,000 | 307,000,000 |
| Other Non Cash Income Expense | -508,000,000 | -604,000,000 | -524,000,000 |
| Change In Accounts Receivable | 171,000,000 | 43,000,000 | 430,000,000 |
| Change In Inventories | 27,000,000 | -598,000,000 | 825,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 212,000,000 | -500,000,000 | 648,000,000 |
| Change In Other Liabilities | 186,000,000 | 802,000,000 | 401,000,000 |
| Cash From Operating Activities | 8,667,000,000 | 8,406,000,000 | 9,154,000,000 |
| Purchases Of Marketable Securities | 3,396,000,000 | — | — |
| Sales Of Marketable Securities | 1,770,000,000 | — | — |
| Acquisition Of Property Plant And Equipment | 1,400,000,000 | 1,479,000,000 | 2,243,000,000 |
| Acquisition Of Business | 3,132,000,000 | 3,660,000,000 | 39,000,000 |
| Other Investing Activities | -8,000,000 | 160,000,000 | -99,000,000 |
| Cash From Investing Activities | -5,841,000,000 | -5,142,000,000 | -2,159,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 596,000,000 | 541,000,000 | 471,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 4,000,000,000 | 3,000,000,000 | 3,000,000,000 |
| Issuance Of Long Term Debt | 1,204,000,000 | 5,942,000,000 | 3,193,000,000 |
| Repayment Of Long Term Debt | 3,607,000,000 | 5,782,000,000 | 375,000,000 |
| Other Financing Activities | 195,000,000 | 56,000,000 | -9,000,000 |
| Cash From Financing Activities | -6,792,000,000 | -3,622,000,000 | -2,810,000,000 |
| Change In Cash | -4,057,000,000 | -440,000,000 | 4,046,000,000 |
| Cash At End Of Period | 4,009,000,000 | 8,077,000,000 | 8,524,000,000 |
| Income Taxes Paid | 1,834,000,000 | 1,482,000,000 | 1,234,000,000 |
| Interest Paid | 1,570,000,000 | 1,385,000,000 | 667,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 16.58 | 15.52 | 17.75 |
| Price To Earnings Ratio | 31.377 | 34.2004 | 31.0248 |
| Earnings Growth Rate | 6.8299 | -12.5634 | -9.5311 |
| Price Earnings To Growth Ratio | 4.5941 | -2.7222 | -3.2551 |
| Book Value Per Share | 219.8665 | 219.4663 | 204.449 |
| Price To Book Ratio | 2.3661 | 2.4185 | 2.6935 |
| Ebitda | 10,718,000,000 | 9,880,000,000 | 9,906,000,000 |
| Enterprise Value | 228,004,860,000 | 235,143,940,000 | 247,203,480,000 |
| Dividend Yield | 0.003 | 0.0026 | 0.0022 |
| Dividend Payout Ratio | 0.094 | 0.0908 | 0.0677 |
| Debt To Equity Ratio | 0.6713 | 0.8203 | 0.9063 |
| Capital Expenditures | 1,014,000,000 | 1,236,000,000 | 1,933,000,000 |
| Free Cash Flow | 7,653,000,000 | 7,170,000,000 | 7,221,000,000 |
| Return On Equity | 0.1278 | 0.1274 | 0.1583 |
| One Year Beta | 0.6208 | 0.8876 | 0.9997 |
| Three Year Beta | 0.9048 | 0.9058 | 0.8111 |
| Five Year Beta | 0.8005 | 0.8432 | 0.8699 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| JOHNSON JENNIFER M | Director | 2025-09-27 | 67 | A | 541 |
| Lynch Karen S | Director | 2025-09-27 | 67 | A | 171 |
| Keith R. Alexandra | Director | 2025-09-27 | 67 | A | 1,150 |
| SPERLING SCOTT M | Director | 2025-09-27 | 91 | A | 17,428 |
| WEISLER DION J | Director | 2025-09-27 | 80 | A | 2,573 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Angus S King, Jr. | Senator | 2025-08-18 | Sale (Full) | 2025-07-21 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-06-11 | Purchase | 2025-05-13 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2025-05-12 | Sale (Full) | 2025-04-08 | Joint | $50,001 - $100,000 |
| Markwayne Mullin | Senator | 2023-11-01 | Purchase | 2023-10-03 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2023-10-12 | Purchase | 2023-09-13 | Joint | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Sale | 2025-03-03 | Spouse | $1,001 - $15,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2024-10-29 | Spouse | $1,001 - $15,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2025-06-06 | Spouse | $1,001 - $15,000 |
| Kelly Louise Morrison | 2025-09-11 | MN03 | Sale (Partial) | 2025-08-19 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Capital Advisors Wealth Management, LLC | 2025-09-30 | 268,843 | 554 | 485.2762 |
| Raub Brock Capital Management LP | 2025-09-30 | 291,012 | 600 | 485.02 |
| Financial Management Professionals, Inc. | 2025-09-30 | 109,707 | 226 | 485.4292 |
| CWM, LLC | 2025-09-30 | 7,730,000 | 15,937 | 485.0348 |
| Canoe Financial LP | 2025-09-30 | 4,365,180 | 9,000 | 485.02 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| CAPITAL MANAGEMENT INVESTMENT TRUST | 2025-08-31 | Institutional Shares | WSACX | 1,300 | 640,536 | 1.02 |
| NORTH COUNTRY FUNDS | 2025-08-31 | The North Country Large Cap Equity Fund | NCEGX | 3,100 | 1,527,432 | 1.1966 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 1,492 | 697,778.56 | 0.2918 |
| ETF Series Solutions | 2025-07-31 | Aptus Drawdown Managed Equity ETF | ADME | 4,284 | 2,003,541.12 | 0.889 |
| ETF Series Solutions | 2025-07-31 | Aptus Collared Investment Opportunity ETF | ACIO | 38,299 | 17,911,676.32 | 0.8902 |